Skip to content
TickerMagic

SMS Pharmaceuticals Limited

SMSPHARMANSEHealthcare
₹481.35
+4.55 (+0.95%) · EOD 2026-11-20

Our verdict

Buy

Momentum (95/100) does the heavy lifting; valuation (44/100) is the drag.

Buy zoneHealth A
Quality 60Momentum 95Value 44Trend 66The Spark ↓

Our fair value

Overvalued by 13%
₹417.54down 13.26%
Price ₹481Range ₹241 – ₹451

Buy-below (20% margin of safety): ₹334.03

The bottom line

Our blended model reads SMS Pharmaceuticals Limited as a Buy at 63/100. We put fair value near ₹417.54; at ₹481.35 that leaves roughly 13% downside, so the stock screens overvalued by 13%. On 34.2x trailing earnings it sits roughly in line with the Healthcare median of about 37.4x. The price is about 8% below its 52-week high of ₹525.5 and 77% above the low of ₹271.32. Financial health scores 84/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 5/9. It clears 7 of 13 investability checks, with durability 60, valuation 61 and momentum 95 on our 0–100 scales.

Analysis by Ankit Sharma · TickerMagic's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.

Intrinsic value
Our fair value
₹417.54down 13.26%
Overvalued by 13%
Price ₹481.35Range ₹240.68–₹450.94
DCF + relative blendhigh confidence

With a 20% margin of safety, our buy-below price is ₹334.03.

1-year price

EOD · 2026-11-20
1D
up 0.95%
1W
down 8.11%
1M
up 10.74%
3M
up 34.07%
6M
up 17.43%
1Y
—

52-week range

-8.40% from the 52-week high.

Trend check
Above 50-DMA₹462Above 200-DMA₹401

Price above both moving averages reads as an intact uptrend; below both, the trend is against you.

Verdict pillars

Buy63
A
Financial health 84/100
Altman Z 4.36 · Safe zone

Piotroski F-score 5/9 — quality of earnings & balance sheet.

Our scores

Durability60
Valuation61
Momentum95

Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.

Investability checklist

Passed 7 of 13 checks
Each check screens one fundamentals, valuation or trend signal.
  • Fail: ROE above 15%: 14.3%
  • Pass: Low debt (D/E < 0.5): 0.46x
  • Fail: Positive free cash flow
  • Fail: Revenue growth > 10%: -4%
  • Pass: Earnings growing: 49%
  • Pass: Net margin ≥ 10%: 11.5%
  • Pass: Current ratio > 1.5: 1.81
  • Fail: Below our fair value
  • Fail: Margin of safety ≥ 20%
  • Pass: Above 200-day average
  • Pass: Above 50-day average
  • No data: Positive 1-year return
  • Pass: Altman Z in safe zone: Z 4.36
  • Fail: Piotroski ≥ 7: 5/9

Shareholding

  • Promoter76.5%
  • Institutions2.8%
  • Public & other20.6%

Promoter holding via insider stake; institutional via reported holdings.

Key fundamentals

Market cap
₹3,569 Cr
P/E ratio
34.2
P/B ratio
4.54
EPS (TTM)
₹11.15
ROE
14.3%
Debt / Equity
0.46x
Profit margin
11.5%
Free cash flow
₹-95 Cr
52-week high
₹525.5
-8.40% from high
52-week low
₹271.32
Dividend yield
0.1%
Beta
0.30
SWOT snapshot

Bull case vs bear case

Bull case

Strengths

  • Financially solid — Altman Z 4.36.

Opportunities

  • Earnings growing (49% YoY).
  • Trading in our value buy zone versus sector peers.

About SMS Pharmaceuticals Limited

SMS Pharmaceuticals Limited manufactures and sells active pharmaceutical ingredients and intermediates globally. Its product portfolio spans anti-retroviral, anti-inflammatory, anti-viral, anti-diabetic, anti-fungal, anti-epileptic, anti-migraine, anti-coagulant, anti-psychotic, anti-anginal, and anti-ulcer categories. The company also conducts contract research on peptides.

SMS Pharmaceuticals Limited — frequently asked questions

Is SMS Pharmaceuticals Limited a buy, hold or sell?

TickerMagic currently rates SMS Pharmaceuticals Limited (SMSPHARMA) a Buy, based on a blended score of 63/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.

What is SMS Pharmaceuticals Limited's fair value?

Our blended DCF and relative-valuation model estimates SMS Pharmaceuticals Limited's fair value at about ₹417.54, versus a current price of ₹481.35 — roughly 13% downside. On that basis the stock looks overvalued by 13%.

Is SMS Pharmaceuticals Limited financially healthy?

SMS Pharmaceuticals Limited scores 84/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 5/9.

How has SMS Pharmaceuticals Limited's share price performed?

SMS Pharmaceuticals Limited is up 34% over three months, and last traded at ₹481.35. Past performance doesn't predict future returns.

Our verdict, fair value, financial-health and checklist are TickerMagic's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.